Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel
- PMID: 24635665
- PMCID: PMC4146407
- DOI: 10.1111/jgs.12730
Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel
Abstract
Noncognitive neuropsychiatric symptoms (NPS) of dementia (aggression, agitation, depression, anxiety, delusions, hallucinations, apathy, disinhibition) affect individuals with dementia nearly universally across dementia stages and etiologies. NPS are associated with poor outcomes for individuals with dementia and caregivers, including excess morbidity and mortality, greater healthcare use, and earlier nursing home placement, as well as caregiver stress, depression, and difficulty with employment. Although the Food and Drug Administration has not approved pharmacotherapy for NPS, psychotropic medications are frequently used to manage these symptoms, but in the few cases of proven pharmacological efficacy, significant risk of adverse effects may offset benefits. There is evidence of efficacy and limited potential for adverse effects of nonpharmacological treatments, typically considered first line, but their uptake as preferred treatments remains inadequate in real-world clinical settings. Thus, the field currently finds itself in a predicament in terms of management of these difficult symptoms. It was in this context that the University of Michigan Program for Positive Aging, working in collaboration with the Johns Hopkins Alzheimer's Disease Research Center and Center for Innovative Care in Aging sponsored and convened a multidisciplinary expert panel in Detroit, Michigan, in fall 2011 with three objectives: to define critical elements of care for NPS in dementia; to construct an approach describing the sequential and iterative steps of managing NPS in real-world clinical settings that can be used as a basis for integrating nonpharmacological and pharmacological approaches; and to discuss how the approach generated could be implemented in research and clinical care.
Keywords: behavior; behavioral management; non-pharmacological management.
© Published 2014. This article is a U.S. Government work and is in the public domain in the U.S.A.
Conflict of interest statement
Dr. Gitlin: grant support through NIH, Alzheimer’s Association; Member on the Fall Advisory Committee for Phillips Lifeline; honoraria for various speaking engagements.
Dr. Lyketsos: grant support (research or CME) from the National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, the National Football League (NFL), Elan, and Functional Neuromodulation Inc; consultant/advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lund beck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel; and receipt of an honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor.
Figures
Similar articles
-
The role of the occupational therapist in the management of neuropsychiatric symptoms of dementia in clinical settings.Occup Ther Health Care. 2014 Jan;28(1):4-20. doi: 10.3109/07380577.2013.867468. Occup Ther Health Care. 2014. PMID: 24354328 Free PMC article.
-
Treatment outcomes of a crisis intervention program for dementia with severe psychiatric complications: the Kansas bridge project.Gerontologist. 2013 Feb;53(1):102-12. doi: 10.1093/geront/gns104. Epub 2012 Aug 30. Gerontologist. 2013. PMID: 22936530 Free PMC article. Clinical Trial.
-
Adjunctive Therapy to Manage Neuropsychiatric Symptoms in Moderate and Severe Dementia: Randomized Clinical Trial Using an Outpatient Version of Tailored Activity Program.J Alzheimers Dis. 2021;83(1):475-486. doi: 10.3233/JAD-210142. J Alzheimers Dis. 2021. PMID: 34334394 Clinical Trial.
-
Dementia Is More Than Memory Loss: Neuropsychiatric Symptoms of Dementia and Their Nonpharmacological and Pharmacological Management.Am J Psychiatry. 2022 Aug;179(8):528-543. doi: 10.1176/appi.ajp.20220508. Am J Psychiatry. 2022. PMID: 35921394 Review.
-
Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA.Drugs R D. 2019 Jun;19(2):93-115. doi: 10.1007/s40268-019-0272-1. Drugs R D. 2019. PMID: 31098864 Free PMC article. Review.
Cited by
-
Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)-Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems.Pharmaceutics. 2024 Sep 27;16(10):1253. doi: 10.3390/pharmaceutics16101253. Pharmaceutics. 2024. PMID: 39458585 Free PMC article.
-
The Association Between Distinct Delusional Ideations and Depressive Symptoms in Alzheimer's Disease: A Re-Analysis of CATIE-AD.J Alzheimers Dis. 2024;101(2):661-670. doi: 10.3233/JAD-240702. J Alzheimers Dis. 2024. PMID: 39213078 Free PMC article.
-
Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial.Front Pharmacol. 2024 Aug 1;15:1417851. doi: 10.3389/fphar.2024.1417851. eCollection 2024. Front Pharmacol. 2024. PMID: 39148533 Free PMC article.
-
The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia.Drugs Aging. 2024 Oct;41(10):847-858. doi: 10.1007/s40266-024-01134-9. Epub 2024 Aug 9. Drugs Aging. 2024. PMID: 39120787 Free PMC article.
-
Assessing behavioral and psychological symptoms of dementia: a comprehensive review of current options and future perspectives.Front Dement. 2023 Jul 25;2:1226060. doi: 10.3389/frdem.2023.1226060. eCollection 2023. Front Dement. 2023. PMID: 39082001 Free PMC article. Review.
References
-
- Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005;293:596–608. - PubMed
-
- Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–408. - PubMed
-
- Kales HC, Chen P, Blow FC, et al. Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression. Am J Geriatr Psychiatry. 2005;13:441–449. - PubMed
-
- Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090–2097. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
